GHENT, Belgium, Jan. 7, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday 14 January 2016 at 10:30 a.m. Pacific Standard Time (07:30 p.m. Central Eastern Time).
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of Ablynx. The presentation will provide an overview of the major achievements in 2015 as well as an update on the Company's proprietary key clinical assets, its partnered programmes and the outlook for 2016.
The presentation will be webcast live and can be accessed on the day via this link. A replay of the webcast will be available on the Company's website, under the news & events section, for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
t: +44 (0)20 7866 7905
Belgium/Dutch and French language
t: +32 (0)2 626 9500
Pdf version of the press release http://hugin.info/137912/R/1976678/723490.pdf